Physician profile
Javed A Malik
NPI 1487652350
$981.16
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $42.66 · 2021: $129 · 2022: $305 · 2023: $266 · 2024: $93.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $186.17 | 2023 | Mitraclip, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $174.68 | 2019-2023 | |
| Boston Scientific Corporation | $120.02 | 2022 | |
| Amgen INC. | $82.80 | 2019 | |
| Nevro Corp. | $78.59 | 2021 | |
| Novo Nordisk INC | $66.17 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $58.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $43.87 | 2024 | |
| Lilly USA, LLC | $38.94 | 2020-2024 | Zepbound |
| Sanofi-Aventis U.S. LLC | $30.28 | 2022 | |
| Dexcom, INC. | $21.88 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $18.84 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $18.44 | 2022 | |
| Pfizer INC. | $16.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.89 | 2024 | Eliquis |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.